AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18639450 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (IRI), Leucovorin (LV), and bolus 5-fluorouracil (5FU) administered weekly (80 mg/m2 IV IRI, 200 mg/m2 LV, 450 mg/m2 bolus 5FU) for six cycles followed by pelvic irradiation plus 5FU.
Number of subjects: 321
Study 18639450 — intervention group
Group type: COMPARATOR
Intervention: Control group: Leucovorin (LV) and bolus 5-fluorouracil (5FU) (200 mg/m2 LV and 450 mg/m2 IV bolus 5FU) for six cycles followed by pelvic irradiation plus 5FU.
Number of subjects: 321
Study 18639450 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (IRI) arm
Number of subjects: 321
Study 18639450 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 321
Study 15947501 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetyl‐L‐carnitine, n‐3 fatty acids, and coenzyme Q10 (Phototrop)
Number of subjects: 106
Study 15947501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 12757966 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg sublingual buprenorphine tablets administered four times a day
Number of subjects: 63
Study 12757966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 10496704 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-tip, high-flow polyurethane catheter (MedComp AshSplit 14.5 F)
Number of subjects: 24
Study 10496704 — intervention group
Group type: COMPARATOR
Intervention: Conventional silicone catheter (Bard Hickman 13.5 F)
Number of subjects: 24
Study 8998896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented total hip arthroplasty
Number of subjects: 0
Study 8998896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless total hip arthroplasty
Number of subjects: 0
Study 8998896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented acetabular components
Number of subjects: 0
Study 8998896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless sockets
Number of subjects: 0
Study 8998896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented femoral component
Number of subjects: 0
Study 1707646 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 1707646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 0
Study 1707646 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enalapril and sulindac
Number of subjects: 0
Study 1707646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6957156 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil (Lopid)
Number of subjects: 0
Study 30420616 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months (3M) adjuvant chemotherapy
Number of subjects: 6088
Study 30420616 — intervention group
Group type: COMPARATOR
Intervention: 6 months (6M) adjuvant chemotherapy
Number of subjects: 6088
Study 27465309 — intervention group
Group type: EXPERIMENTAL
Intervention: Contamination-focused exposure therapy (3 sessions of 30 minutes each)
Number of subjects: 34
Study 27465309 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 34
Study 27465309 — intervention group
Group type: EXPERIMENTAL
Intervention: Contamination-focused exposure therapy
Number of subjects: 34
Study 24273218 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole soy (40 g soy flour)
Number of subjects: 270
Study 24273218 — intervention group
Group type: COMPARATOR
Intervention: Purified daidzein (63 mg)
Number of subjects: 270
Study 24273218 — intervention group
Group type: COMPARATOR
Intervention: Low-fat milk powder (placebo)
Number of subjects: 270
Study 22941466 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAM8 positive tumors
Number of subjects: 126
Study 22941466 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAM8 expression
Number of subjects: 126
Study 22941466 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of ADAM8
Number of subjects: 126
Study 22941466 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAM8 protein expression in tissues
Number of subjects: 126
Study 22941466 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with clinicopathological parameters
Number of subjects: 126
Study 20635286 — intervention group
Group type: EXPERIMENTAL
Intervention: REMAS intervention in psychosocial outpatient treatment
Number of subjects: 0
Study 20635286 — intervention group
Group type: EXPERIMENTAL
Intervention: REMAS intervention in methadone programs
Number of subjects: 0
Study 20635286 — intervention group
Group type: COMPARATOR
Intervention: HIV education control condition
Number of subjects: 0
Study 18979163 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20-microg
Number of subjects: 154
Study 18979163 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 40-microg
Number of subjects: 154
Study 18979163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 16521631 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin 6400 IU subcutaneously once daily for 7 days
Number of subjects: 897
Study 16521631 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (IV bolus of 5000 IU followed by infusion of 800 to 1000 IU/hour for 48 hours, then 5000 IU subcutaneously every 6 hours for 5 days)
Number of subjects: 897
Study 16521631 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 897
Study 16521631 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin 6400 IU
Number of subjects: 897
Study 12670809 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-opioid regimen (ketorolac, clonidine, lidocaine, ketamine, magnesium sulfate, methylprednisolone)
Number of subjects: 30
Study 12670809 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 30
Study 12670809 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and non-opioid
Number of subjects: 30
Study 10790000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin
Number of subjects: 13
Study 10790000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8681660 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (800 micrograms beclomethasone dipropionate)
Number of subjects: 0
Study 1992412 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin, 500 mg three times daily for 14 days
Number of subjects: 108
Study 1992412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 1992412 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 108
Study 6650445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phytate (equivalent to 2% phytic acid based on the starch portion)
Number of subjects: 0
Study 6650445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phytate (added to unleavened bread)
Number of subjects: 0
Study 6650445 — intervention group
Group type: EXPERIMENTAL
Intervention: High phytate bread
Number of subjects: 0
Study 6650445 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (added to reverse the effect of phytic acid)
Number of subjects: 0
Study 31470410 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdural drainage (cohort A)
Number of subjects: 361
Study 31470410 — intervention group
Group type: COMPARATOR
Intervention: Subgaleal drainage (cohort B)
Number of subjects: 361
Study 29579024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft Palate Simulator
Number of subjects: 10
Study 28204607 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid administration of aripiprazole once-monthly 400 mg (single-dose)
Number of subjects: 173
Study 28204607 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid administration of aripiprazole once-monthly 400 mg (multiple-dose)
Number of subjects: 173
Study 28204607 — intervention group
Group type: COMPARATOR
Intervention: Gluteal administration of aripiprazole once-monthly 400 mg (single-dose)
Number of subjects: 173
Study 28204607 — intervention group
Group type: COMPARATOR
Intervention: Gluteal administration of aripiprazole once-monthly 400 mg (multiple-dose)
Number of subjects: 173
Study 28204607 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid and gluteal administration of aripiprazole once-monthly 400 mg
Number of subjects: 173
Study 26523029 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (50 min of walking followed by stretching exercises, 3 times a week for 12 weeks)
Number of subjects: 70
Study 26523029 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (IG)
Number of subjects: 70
Study 26523029 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises (CG)
Number of subjects: 70
Study 23715094 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism spectrum disorders group
Number of subjects: 80
Study 23715094 — intervention group
Group type: COMPARATOR
Intervention: Typically developing group
Number of subjects: 80
Study 23715094 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 21603892 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam (1 mg)
Number of subjects: 20
Study 21603892 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 19100012 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo therapy
Number of subjects: 80
Study 19100012 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 80
Study 17238402 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Language Processing system for automatic extraction of medical problems from clinical free-text documents
Number of subjects: 105
Study 17238402 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 105
Study 12814463 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 9
Study 12814463 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 9
Study 12814463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10626971 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 20
Study 10626971 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulfadiazine
Number of subjects: 20
Study 9356558 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal therapy
Number of subjects: 151
Study 9356558 — intervention group
Group type: COMPARATOR
Intervention: Family therapy
Number of subjects: 151
Study 9356558 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 151
Study 8182269 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger-stick assay for anti-HAV using whole blood on paper discs
Number of subjects: 0
Study 8182269 — intervention group
Group type: COMPARATOR
Intervention: Modified HAVAB method
Number of subjects: 0
Study 3542088 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of dry cold air (causing significant bronchoconstriction)
Number of subjects: 12
Study 3542088 — intervention group
Group type: COMPARATOR
Intervention: Methacholine test without prior cold air inhalation
Number of subjects: 12
Study 29848147 — intervention group
Group type: EXPERIMENTAL
Intervention: Seltorexant 40 mg for five days
Number of subjects: 27
Study 29848147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 27320368 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 67
Study 27320368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 27647059 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm handoff
Number of subjects: 100
Study 27647059 — intervention group
Group type: COMPARATOR
Intervention: Fax referral
Number of subjects: 100
Study 22360575 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs 7630 (3 × 10 drops/day for ages 1-6 years, 3 × 20 drops/day for ages >6-12 years, 3 × 30 drops/day for ages >12-18 years)
Number of subjects: 220
Study 22360575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 20308694 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive multinutrient supplement (SUPP)
Number of subjects: 12
Study 18341416 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Raman spectroscopy with Mahalanobis distance, spectral residuals, and limit test methodology
Number of subjects: 15
Study 18341416 — intervention group
Group type: COMPARATOR
Intervention: Normal ovarian tissues
Number of subjects: 15
Study 18341416 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant ovarian tissues
Number of subjects: 15
Study 15739035 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (Aln, 10 mg/day) plus Raloxifene (Rlx, 60 mg/day)
Number of subjects: 1100
Study 15739035 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (Aln, 10 mg/day) plus Hormone Replacement Therapy (HRT, 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate)
Number of subjects: 1100
Study 15739035 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (Aln) alone
Number of subjects: 1100
Study 15739035 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) alone
Number of subjects: 1100
Study 15739035 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (Rlx) alone
Number of subjects: 1100
Study 11994888 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 3-12 mg/day
Number of subjects: 90
Study 11994888 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 0.5-2 mg/day
Number of subjects: 90
Study 11994888 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of rivastigmine and risperidone
Number of subjects: 90
Study 10349921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium administered with sevoflurane 2% (group 2)
Number of subjects: 40
Study 10349921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium administered with sevoflurane 2% after 30 min (group 3)
Number of subjects: 40
Study 10349921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium administered with sevoflurane 2% after 60 min (group 4)
Number of subjects: 40
Study 10349921 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 40
Study 8602306 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot goserelin, 3.6 mg subcutaneous implant given monthly
Number of subjects: 60
Study 8602306 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol, 200 mg two times per day
Number of subjects: 60
Study 1760910 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna tablets
Number of subjects: 0
Study 1760910 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulphate powder
Number of subjects: 0
Study 1760910 — intervention group
Group type: COMPARATOR
Intervention: Control (no bowel preparation)
Number of subjects: 0
Study 1760910 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna tablets and Sodium picosulphate powder
Number of subjects: 0
Study 1760910 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxatives (general)
Number of subjects: 0
Study 6109500 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (1.5 mg/kg over a period of one hour)
Number of subjects: 20
Study 6109500 — intervention group
Group type: COMPARATOR
Intervention: Control (no respiratory analeptic)
Number of subjects: 20
Study 31087640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated whole breast radiotherapy (HF‐WBRT)
Number of subjects: 1171
Study 31087640 — intervention group
Group type: COMPARATOR
Intervention: Guideline publications
Number of subjects: 1171
Study 31087640 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and/or tumour bed boost radiotherapy (TBBR)
Number of subjects: 1171
Study 31087640 — intervention group
Group type: COMPARATOR
Intervention: Individual clinicians
Number of subjects: 1171
Study 28748002 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum folate concentrations (>45.3 nmol/L)
Number of subjects: 249
Study 28748002 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum folate concentrations
Number of subjects: 249
Study 28748002 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 concentrations
Number of subjects: 249
Study 28748002 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid fortification
Number of subjects: 249
Study 25547776 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Number of subjects: 8
Study 25547776 — intervention group
Group type: COMPARATOR
Intervention: CS-tDCS
Number of subjects: 8
Study 24228854 — intervention group
Group type: EXPERIMENTAL
Intervention: Monday to Saturday rehabilitation (additional Saturday rehabilitation comprising physiotherapy and occupational therapy)
Number of subjects: 996
Study 24228854 — intervention group
Group type: COMPARATOR
Intervention: Usual care Monday to Friday rehabilitation
Number of subjects: 996
Study 17473036 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use quitline
Number of subjects: 82
Study 17473036 — intervention group
Group type: COMPARATOR
Intervention: Brief counseling
Number of subjects: 82
Study 14977577 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (RA)
Number of subjects: 0
Study 14977577 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (RA) aged 45-55 years
Number of subjects: 0
Study 14977577 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (RA) aged 55 years and older
Number of subjects: 0
Study 14977577 — intervention group
Group type: EXPERIMENTAL
Intervention: RA patients treated with prednisone
Number of subjects: 0
Study 10792560 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (2 mg oestradiol valerate for the first 3 months with the addition of 10 mg medroxyprogesterone for 10 days every third month thereafter)
Number of subjects: 51
Study 10792560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 9422466 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback of body center of gravity during postural training (visual feedback)
Number of subjects: 0
Study 9422466 — intervention group
Group type: COMPARATOR
Intervention: No feedback (NFB) group
Number of subjects: 0
Study 8312288 — intervention group
Group type: EXPERIMENTAL
Intervention: ARREST intervention (three 90-minute sessions)
Number of subjects: 87
Study 8312288 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 87
Study 3018228 — intervention group
Group type: EXPERIMENTAL
Intervention: ketocyclazocine
Number of subjects: 10
Study 3018228 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclazocine
Number of subjects: 10
Study 3018228 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine
Number of subjects: 10
Study 3018228 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 31486356 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast skipping (no breakfast)
Number of subjects: 9
Study 31486356 — intervention group
Group type: COMPARATOR
Intervention: Breakfast consumption (three-meal condition)
Number of subjects: 9
Study 30095022 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 supplement 40,000 IU/week
Number of subjects: 88
Study 30095022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 27318427 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen Outreach Program (TOP)
Number of subjects: 7976
Study 27318427 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 7976
Study 24528693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish diet (n = 11)
Number of subjects: 33
Study 24528693 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean fish diet (n = 12)
Number of subjects: 33
Study 24528693 — intervention group
Group type: COMPARATOR
Intervention: Control diet (n = 10)
Number of subjects: 33
Study 22410658 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.25% timolol maleate gel
Number of subjects: 23
Study 22410658 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 23
Study 19156926 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) treatment
Number of subjects: 24
Study 19156926 — intervention group
Group type: COMPARATOR
Intervention: Control group (tumor-free patients)
Number of subjects: 24
Study 19156926 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat surgeries
Number of subjects: 24
Study 17227902 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m2 every 28 days
Number of subjects: 474
Study 17227902 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 1.5 mg/m2 for 5 days every 21 days
Number of subjects: 474
Study 15753495 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (0.3 mg.kg(‐1))
Number of subjects: 64
Study 15753495 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (0.1 mg.kg(‐1))
Number of subjects: 64
Study 15753495 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control Group)
Number of subjects: 64
Study 15753495 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (0.1 and 0.3 mg.kg(‐1))
Number of subjects: 64
Study 11948832 — intervention group
Group type: EXPERIMENTAL
Intervention: NC100150 (between 0.75 and 6 mg of Fe/kg of body weight)
Number of subjects: 9
Study 11948832 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose NC100150
Number of subjects: 9
Study 11948832 — intervention group
Group type: EXPERIMENTAL
Intervention: NC100150
Number of subjects: 9
Study 9465799 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (400 micrograms intravenously every 8 hours four times)
Number of subjects: 370
Study 9465799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 8556665 — intervention group
Group type: COMPARATOR
Intervention: Phone-call support from nurses
Number of subjects: 293
Study 8556665 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving counselling
Number of subjects: 293
Study 8556665 — intervention group
Group type: COMPARATOR
Intervention: Phone-call support
Number of subjects: 293
Study 2165899 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortolone (15-30 mg)
Number of subjects: 48
Study 366721 — intervention group
Group type: EXPERIMENTAL
Intervention: Benoxaprofen (300 mg on the first day followed by 100 mg twice daily)
Number of subjects: 0
Study 366721 — intervention group
Group type: EXPERIMENTAL
Intervention: Benoxaprofen
Number of subjects: 0